Cipla Gets USFDA Approval For Ventolin Generic; Shares Rise 3.08%

Mumbai, April 23: US Food and Drug Administration has granted final approval to Cipla’s subsidiary, Cipla USA Inc., to launch its version of a widely used asthma inhaler and deepening its play in the respiratory segment. 

The Albuterol Sulfate Inhalation Aerosol, 90 mcg per actuation is the first AB-rated generic equivalent of Ventolin HFA, a product originally marketed by GlaxoSmithKline, a company release to the exchanges said. 

An AB rating indicates that the generic drug is therapeutically equivalent to the branded product, allowing pharmacists in the U.S. to substitute it directly, subject to state laws.  

The inhaler is used to treat and prevent bronchospasm in both adults and children aged four years and above. It also addresses exercise-induced respiratory symptoms, making it a staple in asthma care. 

Stock Market Snapshot 

Cipla share price moved up on April 23, 2026, as investors priced in the commercial potential of the approval. 

The stock traded at ₹1,274.40, up 3.08% as of 10:54 IST, compared with the previous close of ₹1,236.30. The company, citing IQVIA data, pegged the US albuterol market at around $1.5 billion.  

Strategic Implications for US Business 

Cipla has been investing in complex inhalation therapies, a space that comes with higher entry barriers. This approval adds another piece to that puzzle, strengthening its presence in the US respiratory portfolio alongside existing offerings. 

Manufacturing will be handled at its dedicated inhalation facility in Fall River, Massachusetts. Local manufacturing not only supports supply reliability but also aligns with regulatory expectations and market access dynamics in the US. 

The product is expected to be launched in the first half of financial year 2026-27, which means the commercial impact will unfold over time rather than immediately. 

Company Background 

Cipla Limited has long been associated with respiratory therapies, alongside its work in antiretroviral and other complex generics. Founded in 1935, the company has grown into a global pharmaceutical player with a presence across regulated and emerging markets. 

Its strength lies in combining manufacturing scale with specialised delivery systems, particularly in inhalation products. Over the years, it has built a vertically integrated platform that supports both development and production. 

Conclusion 

The USFDA approval expands Cipla’s footprint in a competitive but valuable segment and adds depth to its US business. 

Source: 

• https://www.nseindia.com/get-quote/equity/CIPLA/Cipla-Limited 
• https://nsearchives.nseindia.com/corporate/CIPLA_23042026094557_gVentolonSEIntimationv2Signed.pdf